A Start of a New Chapter
- 58% of people responded to ELREXFIO in a clinical trial
- 82% of those people were predicted to still be responding at 9 MONTHS This is also known as the duration of response.
ELREXFIO was studied in 97 people with relapsed or refractory multiple myeloma who had never tried a BCMA-directed therapy and had already been on at least 4 prior treatment regimens.
ELREXFIO is a type of treatment called a BCMA-directed bispecific antibody for people with relapsed or refractory multiple myeloma.
ELREXFIO treats adults with relapsed or refractory multiple myeloma who have already received at least 4 treatment regimens and their cancer has come back or did not respond to treatment.
ELREXFIO is approved based on patient responses and durability of response. There are ongoing studies to confirm its clinical benefit. It is not known if ELREXFIO is safe and effective in children.
As little as $0*
You may pay as little as $0 per treatment for ELREXFIO.
*Eligible, commercially insured patients may pay as little as $0 per treatment for ELREXFIO, regardless of income. Limits, terms, and conditions apply. Patients may receive up to $25,000 in savings annually.
Important updates
Sign up to receive important information and updates about ELREXFIO.
Turn to Pfizer Oncology Together to learn about financial assistance resources and get one-on-one support from a Patient Access Navigator.